HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry

BACKGROUND: Maraviroc (MVC) and other CCR5 antagonists are HIV-1 entry inhibitors that bind to- and alter the conformation of CCR5, such that CCR5 is no longer recognized by the viral gp120 envelope (Env) glycoproteins. Resistance to CCR5 antagonists results from HIV-1 Env acquiring the ability to u...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Roche, Michael, Jakobsen, Martin R, Ellett, Anne, Salimiseyedabad, Hamid, Jubb, Becky, Westby, Mike, Lee, Benhur, Lewin, Sharon R, Churchill, Melissa J, Gorry, Paul R
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2011
Matèries:
Short Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3217884/
https://ncbi.nlm.nih.gov/pubmed/22054077
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1742-4690-8-89
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars